Clinicopathological characteristics of mice with CML-like leukemia treated with MHC-mismatched DLI
. | . | . | CML* . | . | . | . | . | . | GvHD† . | . | . | . | . | . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | PBL, × 103/μL . | . | . | . | . | . | PBL, × 103/μL . | . | . | . | . | ||||||||||
| Experimental group . | No. . | Median survival, d . | Freq, % . | Day 17-22 . | Day 23-49 . | GFP+ %‡ . | Chim, %§ . | Spleen wt, mg . | Freq % . | Day 17-22 . | Day 23-49 . | GFP+ %‡ . | Chim, %§ . | Spleen wt, mg . | ||||||||||
| Non-chimeric, no DLI | 15 | 21.5 | 100 | 50 ± 11 | 92 ± 21 | 54 ± 4 | NA | 531 ± 60 | 0 | NA | NA | NA | NA | NA | ||||||||||
| Chimeric, no DLI | 12 | 22.5∥ | 100¶ | 42 ± 10 | 125 ± 38# | 60 ± 3 | 9 ± 2 | 600 ± 25# | 0 | NA | NA | NA | NA | NA | ||||||||||
| Chimeric, + DLI | 41 | 28.0∥ | 32¶ | 42 ± 11 | 91 ± 17 | 61 ± 4 | 4 ± 2 | 502 ± 27 | 68 | 14 ± 3 | 10 ± 1# | 2 ± 0 | 78 ± 3 | 108 ± 8# | ||||||||||
| Splenocytes at BMT | 6 | 53 | 0 | NA | NA | NA | NA | NA | 100 | 3 ± 0.8 | 2 ± 0.4 | 2 ± 1 | 67 ± 4 | 23 ± 6 | ||||||||||
. | . | . | CML* . | . | . | . | . | . | GvHD† . | . | . | . | . | . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | PBL, × 103/μL . | . | . | . | . | . | PBL, × 103/μL . | . | . | . | . | ||||||||||
| Experimental group . | No. . | Median survival, d . | Freq, % . | Day 17-22 . | Day 23-49 . | GFP+ %‡ . | Chim, %§ . | Spleen wt, mg . | Freq % . | Day 17-22 . | Day 23-49 . | GFP+ %‡ . | Chim, %§ . | Spleen wt, mg . | ||||||||||
| Non-chimeric, no DLI | 15 | 21.5 | 100 | 50 ± 11 | 92 ± 21 | 54 ± 4 | NA | 531 ± 60 | 0 | NA | NA | NA | NA | NA | ||||||||||
| Chimeric, no DLI | 12 | 22.5∥ | 100¶ | 42 ± 10 | 125 ± 38# | 60 ± 3 | 9 ± 2 | 600 ± 25# | 0 | NA | NA | NA | NA | NA | ||||||||||
| Chimeric, + DLI | 41 | 28.0∥ | 32¶ | 42 ± 11 | 91 ± 17 | 61 ± 4 | 4 ± 2 | 502 ± 27 | 68 | 14 ± 3 | 10 ± 1# | 2 ± 0 | 78 ± 3 | 108 ± 8# | ||||||||||
| Splenocytes at BMT | 6 | 53 | 0 | NA | NA | NA | NA | NA | 100 | 3 ± 0.8 | 2 ± 0.4 | 2 ± 1 | 67 ± 4 | 23 ± 6 | ||||||||||
All values are mean ± SE. Freq, indicates frequency; Chim, chimerism; wt, weight; NA, not applicable.
CML-like disease defined by leukocytosis with GFP+/Mac-1+ cells, splenomegaly, pulmonary myeloid infiltrates
GvHD defined by weight loss or diarrhea with mononuclear infiltration of dermis, hepatic portal tracts, and intestinal crypts
Percentage of GFP+ peripheral blood leukocytes at time of morbidity or death
Allogeneic chimerism, defined as percentage of H-2b+ peripheral blood leukocytes at time of morbidity or death
Significantly different (P < .0001, Mantel-Cox test)
Significantly different (P < .0001, Fisher Exact test)
Significantly different for Day 23-49 PBL counts and spleen weights (P < .0001, unpaired t test)